Navidea secures U.S. patent for DAT tracer, eyes Phase III trials

11/17/2013 | Pharmaceutical Business Review Online

Navidea Biopharmaceuticals has received a U.S. patent for its radiolabeled agent that binds to dopamine transporter receptors. The patent for NAV5001 covers the formulation of the tracer, which is used with SPECT to diagnose Parkinsonian syndromes and dementia with Lewy bodies. Phase III clinical trials of NAV5001 are expected to start by the end of the year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC